AI-based diagnostic software provider Paige has introduced an AI software Paige Breast Lymph Node for the detection of breast cancer metastases in lymph nodes.
The software is meant to detect if breast cancer has metastasized to lymph nodes, concurrent with pathologists’ own interpretive review.
The detection of tumour metastasis is time-consuming due to the size of the tissue area and small micro-metastases.
Paige Breast Lymph Node is developed to enhance the accuracy of the detection rate of breast cancer metastases by using AI to identify tumour metastases of any size more efficiently.
It has above 98% slide level sensitivity to identify metastases of any size and is developed to improve diagnostic accuracy for the most modest metastatic foci.
Paige founder and chief medical officer David Klimstra said: “Accurate detection of breast cancer metastases is paramount for physicians and their patients, but it can be a laborious, manual task for pathologists.
“Paige Breast Lymph Node offers pathologists a quicker and more efficient way to analyse large quantities of lymph node tissue, as well as peace of mind for them and their patients.”
The software, based on the same underlying AI technology as Paige Prostate, displays signs of metastatic breast cancer at the individual lymph node level, highlighting all the suspected areas prone to tumours on a slide with the help of Paige’s proprietary TissueMap.
To be offered as part of Paige Breast Suite, Paige Breast Lymph Node is designed for quick deployment in a range of laboratory and hospital settings.
Paige CEO Andy Moye said: “Paige Breast Lymph Node bolsters the value of the Paige Breast Suite to clinical pathologists. This product launch is an important step in our overall commercialization strategy as we bring the power of our AI platform to new disease areas.
“Alongside our FDA-approved Paige Prostate, the generalizability of the AI further validates the broader use of Paige’s software in assisting pathologists to diagnose cancer.”
Paige Breast Lymph Node was showcased at the United States and Canadian Academy of Pathology (USCAP) Annual Meeting, organised between 19-24 March 2022.
